MedWatch

Novo Nordisk exec joins board of Argenx

Argenx, an immunology company developing a treatment for a chronic autoimmune disorder, has appointed Novo Nordisk executive vice president Camilla Sylvest as board member.

Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR

Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk, has been appointed a non-executive director to the Board of Directors of Argenx, the Belgium-based company announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs